| Abstract Objective To evaluate the incidence of unexplained pulmonary hypertension (PH) in end- stage renal disease (ESRD) and to evaluate its possible relationship with some clinical and biochemical parameters. Patients and Methods This study was conducted retrospectively at Prince Rashed Hospital (PRH), North of Jordan, on patients undergoing maintenance hemodialysis (HD) during August 2009 to August 2010.Demographic and clinical data were obtained from charts review and Patients themselves. 2Dimensional echocardiography (2DECHO) was performed in all patients. Blood samples were taken for parathormone (PTH) and other biochemical measurements. SPSS package was used for statistical analysis.Statistical significance was considered at p value < 0.05. Results A total of 131 hemodialysis (HD) patients were included in the study, of them 76 (58, 9%) were men. The mean age of the study population was 53.7 + 16.2 yrs. Pulmonary hypertension (pulmonary artery pressure (PAP)=47+3, range 35-79mmHg) was detected in 52 patients (39.6%).The levels of PAP were positively correlated with serum intact parathormone (iPTH) levels, age, duration of HD, mean arterial pressure (MAP), interventricular septal (IVS) thickness, cardiac output(CO), and serum levels of phosphorus , creatinine, whereas the levels of PAP were inversely correlated with the levels of serum calcium and hemoglobin(Hb). Conclusion Pulmonary hypertension is a frequent finding in end stage renal disease and mineral disorders together with secondary hyperparathyroidism (SHPTH), increased cardiac output and anemia may be involved in the pathogenesis of this abnormality. The early detection and treatment of pulmonary hypertension aiming to decrease its serious complications is mandatory. |
|
1. 1. Rich S, Chomka E, Hasara L, et al. The prevalence of pulmonary hypertension in the United States. Chest 1989; 86:236-4.
2. Simmoneau G, Galie N, Rubin L J, et al. (June 2004). Clinical classification of pulmonary hypertension. J.Am.Coll.Cardiol.43 (12 suppl S);5S-12S:10.1016/j.jacc.2004.02.037.
3. Abramson SV,Burke JF,Kelly JJ Jr, et al. Pulmonary hypertension predicts mortality in patients with dilated cardiomyopathy . Ann Intern Med 1992; 116:888-95.
4. Trad S, Amoura Z, Beigelman C, et al, Pulmonary arterial hypertension is a major motality factor in systemic sclerosis independent of interstitial lung disease. Arthritis Rheum 2006; 54:184-91.
5. Goel N, Mittman N, Bahsin A, et al. Pulmonary hypertension in dialysis patients. J Am Soc Nephrol 2004; 15:323 a.
6. Llach F,Masry SG. On the mechanism of secondary hypertension in moderate renal insufficiency .J Clin Endcrinol Metab 1985; 601-6.
7. Rehman MH, Hossein MM, Sultana S, Jamal C Y, Karim MA. Correlation of serum parathormone level with biochemical parameters in chronic renal failure.Indian Pediatr 2005; 42:250-4.
8. Akmal M, Barndt RR, Absari AN, Mohler JG, Massry SG. Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Internationl, 47, (1995); 158-163.
9. Havlucu Y, Kursat S, Ekmekci C, et al. Pulmonary hypertension in patients with chronic renal failure. Respiration 2007; 74:503-510.
10. Nakhoul F,Yigla M,Gilman R, Reisner S A, Abassi Z. The pathogenesis of pulmonary hypertention in hemodialysis patients via arterio-venous access. Nephrol Dial Transplant (2005)20:168-1692.
11. Galie N, Manes A, Branzi A. Evaluation of pulmonary arterial hypertension. Curr Opin Cardiol; 2004 Nov, 19(6):575-81.
12. Torres F (2007).Systemic review of randomized, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. Int J Clin Pract.61 (10); 1756-65.
13. Goodman WG .Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59:1187-1201.
14. Goodman WG. Historical perspective on the management of calcium and phosphorus metabolism in chronic renal failure: authors replay .Am J Kidney Dis 2001; 37:197-201.
15. Coburn JW, Salusky IB, Norris KC, et al .Oral and parenteral calcitriol for the management of end-stage renal disease .Contrib Nephrol 1991; 90:166-182.
16. Goodman WG, frazao JM, Goodkin DA et al .A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58:436-445.
17. Mucsi I, Hercz G, Uldall R et al .Control of serum phosphorus without any phosphate binders in patients treated with nocturnal hemodialysis .Kidney Int 1998; 53:1399-1404.
18. Mahdavi-Mazadeh M, Alijavad-Mousavi S, Yahyazadeh H, Azdi M,Yoosefnejad H, Ataiipoor Y. Pulmonary hypertension in hemodialysis patients. Saudi J Kidney Dis Transpl, 2008; 19(2):189-193.
19. Bozbas SS, Akcay S, Bozbas H, et al. Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. Transplant Proc.2009; 41(7):273-6.
|
